Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.
about
Interleukin-1β is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki diseaseCordycepin inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)-α production via activating amp-activated protein kinase (AMPK) signalingMizoribine provides effective treatment of sequential histological change of arteritis and reduction of inflammatory cytokines and chemokines in an animal model of Kawasaki disease.Linking classification and therapeutic management of vasculitides.A child with resistant Kawasaki disease successfully treated with anakinra: a case report.Salvianolic Acid B Down-regulates Matrix Metalloproteinase-9 Activity and Expression in Tumor Necrosis Factor-α-induced Human Coronary Artery Endothelial Cells.Etanercept suppresses arteritis in a murine model of kawasaki disease: a comparative study involving different biological agents.The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease.Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population.Management of Kawasaki disease.IL-1 Inhibition May Have an Important Role in Treating Refractory Kawasaki Disease.Non-infectious orbital vasculitides.Epidemiology and management of Kawasaki disease.Management of acute and refractory Kawasaki disease.Kawasaki disease: pathophysiology, clinical manifestations, and management.Transcriptional regulation by infliximab therapy in Kawasaki disease patients with immunoglobulin resistance.Infliximab as rescue therapy in refractory Kawasaki disease.Partial response to anakinra in life-threatening Henoch-Schönlein purpura: case report.Epidemiology of immunoglobulin resistant Kawasaki disease: results from a large, national database.Overview of Pharmacological Treatment Options for Pediatric Patients with Refractory Kawasaki DiseaseKawasaki disease: a comprehensive review of treatment options.Kawasaki disease and coronary artery aneurysms: from childhood to adulthood.Natriuretic Peptides in Kawasaki Disease: the Myocardial Perspective.Review: Found in Translation: International Initiatives Pursuing Interleukin-1 Blockade for Treatment of Acute Kawasaki Disease.Preventing coronary artery lesions in Kawasaki disease.Kawasaki disease: Medical therapies.Effect and Safety of TNF Inhibitors in Immunoglobulin-Resistant Kawasaki Disease: a Meta-analysis.Role of the Egami score to predict immunoglobulin resistance in Kawasaki disease among a Western Mediterranean population.Should infliximab be used as an adjuvant to IVIG in the treatment of children with Kawasaki disease who are at high risk for resistance to conventional therapy?Adjunctive therapies in Kawasaki disease.Analysis of biomarker serum levels in IVIG and infliximab refractory Kawasaki disease patients.Treatment Options for Resistant Kawasaki Disease.Adeno-associated Virus Vector-mediated Interleukin-10 Induction Prevents Vascular Inflammation in a Murine Model of Kawasaki Disease.
P2860
Q24633011-43516AA1-62AD-4A3C-9689-B26B3E66CBCFQ34072358-1B869131-C719-4DB4-A675-23F47738AA3EQ35617543-56397603-F060-4D7C-B981-A5623AE89B0EQ35672892-B9BE6BC7-F235-47F0-95C5-1712267E1A27Q36340938-0DD2D1EE-C1EE-44C8-B4DA-AF19D421E36BQ36531763-D994DADB-509F-446C-97A6-032857E7C922Q36766177-06099D0B-00F3-4E48-9D30-195A32CA3063Q37175810-A18A127C-1388-4F16-9B6D-EAD84483F4F4Q37364378-DA4363A2-475D-476F-9C1C-CF42FDA209EFQ37465500-1BF59C37-E1C7-4D6D-8F25-EE91B9389AADQ37723505-1B6E1DFB-52A9-43BE-8CEA-923FF3AAB7E9Q37987806-AEBEE675-BF5B-4FE8-9DE1-9736EBAFE3CAQ38012529-9B741F5A-B905-4DAC-A5B5-4326EF7D159BQ38063969-E93107F8-BB90-43C2-BC14-8DDBAC8C0129Q38205391-24CDFF04-7B4E-4749-9496-2D1DA89F9BD0Q38306167-A71737DC-6E4A-4AC3-9BC1-7A3597392220Q38349194-2482D8E2-7D20-4D93-8747-9A91744F46FEQ38356731-9899AE6B-305C-40CA-A839-1263730269BAQ38418999-843C8F1E-B9AB-4919-99C8-29F7DED40982Q38546497-463AC9C0-0556-4AAD-81AE-412B7D5C73B7Q38627718-C19F3A25-7E6F-413C-A3B1-BCA4D80898FBQ38638912-F0B5FB6A-2045-4A73-AA84-F1E4D95A77DDQ38719434-6E777DE9-1BB1-434A-83F1-DE2CEEF11171Q38993829-10D0B9BE-77A8-457B-BDC3-8A61E1CE2EECQ39399053-0476CCE2-AF83-4AB8-A7A7-D941E2BCB3A8Q40054079-2D3ADCEB-34E3-4830-93C3-E1C1D289AC44Q40091671-EA4ADC2B-241C-4FC1-BFED-2DE33B12180AQ40740694-90A21839-BFD5-4709-8065-E240E549E95CQ42967833-00D71B46-7F1E-479B-B0F9-F76CE48FA3D7Q45978588-0E86891A-BFE3-4372-A653-30B721A87E22Q47230629-0B47DFF1-7736-4854-83AD-661503720D52Q47660588-F141AB48-0627-4215-B41D-D0A68026448CQ53681768-CDDEF371-2899-4C0D-86C3-569B2EF75E2D
P2860
Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Infliximab for intravenous imm ...... isease: a retrospective study.
@en
Infliximab for intravenous imm ...... isease: a retrospective study.
@nl
type
label
Infliximab for intravenous imm ...... isease: a retrospective study.
@en
Infliximab for intravenous imm ...... isease: a retrospective study.
@nl
prefLabel
Infliximab for intravenous imm ...... isease: a retrospective study.
@en
Infliximab for intravenous imm ...... isease: a retrospective study.
@nl
P2093
P50
P1476
Infliximab for intravenous imm ...... isease: a retrospective study.
@en
P2093
Adriana H Tremoulet
Annette Baker
David R Fulton
Elena Corinaldesi
Jane C Burns
Virginia E Watson
P304
644-649.e1
P356
10.1016/J.JPEDS.2010.10.012
P407
P577
2010-12-03T00:00:00Z